Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma

Xiang, Juanjuan; Tang, Jingqun; Song, Chao; Yang, Zhimin; Hirst, David; Zheng, Qiujian; Li, Gang

doi:10.1080/14653240902960429

Cited by 62 publications

(40 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings suggest that therapies using allogeneic MSCs may also be immune suppressive, and clearly this is a relevant issue that must be addressed in the context of tumor therapy. Lewis lung carcinoma [36] Inhibit growth of lung metastasis and prolong survival VEGFR-1 Lewis lung carcinoma [38] Decrease lung metastases and prolong lifespan HSV-Tk Leptomeningeal glioma [37] Reduce tumor size and prolong survival rMSC HSV-Tk Glioma [39] Tumor growth suppression and survival prolongation Glioblastoma [40,41] iNOS Fibrosarcoma [42] Inhibit tumor growth hBM-MSC, human bone marrow-derived mesenchymal stem cell; hAT-MSC, human adipose tissue-derived mesenchymal stem cell; hUCB-MSC, human umbilical cord blood-derived mesenchymal stem cell; mMSC, mouse bone marrow-derived mesenchymal stem cell; rMSC, rat bone marrow-derived mesenchymal stem cell.…”

Section: Mscs Are Immune Privilegedmentioning

confidence: 99%

“…Subsequently, MSCs from different sources, including human bone marrow-derived MSCs [28][29][30][31], human adipose tissue-derived MSCs (hAT-MSCs) [32,33], human umbilical cord blood-derived mesenchymal stem cells [34], mouse bone marrow-derived MSCs (mMSCs) [35][36][37][38], and rat MSCs [39][40][41][42], have been evaluated as vehicles for tumor therapy. The expression of diverse therapeutic genes, including IFN-b [27,28,30], TRAIL [29,32,34], PEDF [33], IL-12 [35], CX3CL1 [36], VEGFR-1 [38], iNOS [42], and HSV-Tk [37,[39][40][41], has been engineered into MSCs to allow a targeted release of these agents in models of melanoma [27,28], breast cancer [29,35], Lewis lung carcinoma [36], gliomas [30,34,37,39], glioblastoma [40,41], cervical cancer [32], prostate cancer [33], and fibrosarcoma [42]. In each of these tumor models, treatment showed efficacy in the inhibition of local tumor g...…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Stem Cell-Based Tumor-Targeted Gene Therapy in Gastrointestinal Cancer

Bao

Zhao

Nieß

et al. 2012

Stem Cells and Development

View full text Add to dashboard Cite

Mesenchymal stem (or stromal) cells (MSCs) are nonhematopoietic progenitor cells that can be obtained from bone marrow aspirates or adipose tissue, expanded and genetically modified in vitro, and then used for cancer therapeutic strategies in vivo. Here, we review available data regarding the application of MSC-based tumortargeted therapy in gastrointestinal cancer, provide an overview of the general history of MSC-based gene therapy in cancer research, and discuss potential problems associated with the utility of MSC-based therapy such as biosafety, immunoprivilege, transfection methods, and distribution in the host.

show abstract

Section: Mscs Are Immune Privilegedmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cell-Based Tumor-Targeted Gene Therapy in Gastrointestinal Cancer

Bao

Zhao

Nieß

et al. 2012

Stem Cells and Development

View full text Add to dashboard Cite

show abstract

“…This makes them enticing candidates as delivery vehicles of therapeutic agents, in addition to their potential as a cell source for tissue regeneration. Ongoing research into the modification of MSCs for targeted delivery of agents [6,7] is one capacity in which MSCs may serve as a therapeutic delivery vehicle. However, MSCs have also been shown to secrete a wide array of bioactive factors that have the potential to impact tissue remodeling [8,9].…”

mentioning

confidence: 99%

Mesenchymal Stem Cell Stimulation of Tissue Growth Depends on Differentiation State

Rothenberg

Ouyang

Elisseeff

2011

Stem Cells and Development

View full text Add to dashboard Cite

The osteochondral microenvironment involves a complex milieu of cues that facilitate proper tissue development, homeostasis, and repair. This environment is disrupted in disease states such as osteoarthritis. Mesenchymal stem cells (MSCs) are under clinical investigation for the treatment of osteoarthritis given their capacity to differentiate into chondrocytes as well as to secrete a wide array of biologically active factors that support cell proliferation and tissue formation. In fact, the therapeutic action of these cells in many clinical applications is now thought to be at least partially dependent on their secretory capacity. Previous work demonstrated that MSCs were capable of stimulating chondrocyte growth and tissue production, whereas tissue-derived osteoblasts were not stimulatory. This study investigated the stimulatory capacity of MSCs during osteogenesis and the impact of MSC phenotype on cartilage stimulation. Cell interactions were examined in 3 coculture systems to confirm that trends were not dependent on material: traditional cell culture insert coculture, bilayered poly(ethylene glycol) gels, and a scaffold comprised of a layer of poly(ethylene glycol) polymerized onto a poly(lactic-co-glycolic) acid-based scaffold. Results demonstrated that MSCs predifferentiated toward an osteogenic phenotype for 3 days exhibited enhanced stimulation of chondrocyte extracellular matrix production, whereas longer periods of predifferentiation decreased the magnitude of observed stimulation. Further, tissue formation by the MSCs themselves showed greater dependence on the coculture system than the presence of other cells or length of predifferentiation.

show abstract

“…The in vivo experiments confirmed results from in vitro transwell migration studies, which had demonstrated tumor homing of iron nanoparticle-labeled and unlabeled MSCs. The migration potential of MSCs towards tumors could also be shown for murine osteosarcoma (Xu et al, 2009), murine fibrosarcoma (Xiang et al, 2009), and murine glioma models (Nakamizo et al, 2005). The number of MSCs that reaches a site of injury or tumorigenesis after systemic administration may not always be sufficient to have a therapeutic effect.…”

Section: Msc Migration To Cancer Tissuementioning

confidence: 95%